- Home
- MGNX vs PCM Comparison
MGNX vs PCM Comparison
Compare MGNX & PCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- PCM
- Stock Information
- Founded
- MGNX 2000
- PCM 1993
- Country
- MGNX United States
- PCM United States
- Employees
- MGNX N/A
- PCM N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- PCM Trusts Except Educational Religious and Charitable
- Sector
- MGNX Health Care
- PCM Finance
- Exchange
- MGNX Nasdaq
- PCM Nasdaq
- Market Cap
- MGNX 99.7M
- PCM 82.0M
- IPO Year
- MGNX 2013
- PCM N/A
- Fundamental
- Price
- MGNX $1.66
- PCM $6.27
- Analyst Decision
- MGNX Hold
- PCM
- Analyst Count
- MGNX 6
- PCM 0
- Target Price
- MGNX $3.20
- PCM N/A
- AVG Volume (30 Days)
- MGNX 819.6K
- PCM 29.1K
- Earning Date
- MGNX 11-04-2025
- PCM 01-01-0001
- Dividend Yield
- MGNX N/A
- PCM 11.68%
- EPS Growth
- MGNX N/A
- PCM N/A
- EPS
- MGNX N/A
- PCM N/A
- Revenue
- MGNX $165,495,000.00
- PCM N/A
- Revenue This Year
- MGNX N/A
- PCM N/A
- Revenue Next Year
- MGNX N/A
- PCM N/A
- P/E Ratio
- MGNX N/A
- PCM N/A
- Revenue Growth
- MGNX 303.47
- PCM N/A
- 52 Week Low
- MGNX $0.99
- PCM $6.88
- 52 Week High
- MGNX $5.10
- PCM $10.20
- Technical
- Relative Strength Index (RSI)
- MGNX 45.74
- PCM 32.36
- Support Level
- MGNX $1.82
- PCM $6.28
- Resistance Level
- MGNX $2.15
- PCM $6.36
- Average True Range (ATR)
- MGNX 0.14
- PCM 0.14
- MACD
- MGNX -0.02
- PCM -0.03
- Stochastic Oscillator
- MGNX 16.95
- PCM 13.48
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
About PCM PCM Fund Inc.
Pcm Fund Inc is a closed-end investment management company. Its investment objective is to seek current income as a primary focus and also capital appreciation. The Fund invests in agency-guaranteed mortgage-backed securities, private-label mortgage-backed securities, high-yield corporate debt securities, and commercial mortgage-backed securities.